References
- Kessinger A., Armitage J. O., Landmark J. D., Bierman P. J., Weisenburger D. D. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988; 71: 723–727
- Hohaus S., Goldschmit H., Ehrhardt R., Spitzer G., Sahebi F., Lee M., Hua C., Cao J., Lee J. C., Hong C. H., Bearman S., Lill M., Berenson R., Berenson J. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Experimental. Hematology 1993; 21: 508–514
- Chao N. J., Schriber J. R., Grimes K., Long G. D., Negrin R. S., Raimondi C. M., Horning S. J., Brown S. L., Miller L., Blume K. J. Granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031–2035
- Ketterer N., Salles G., Raba M., Espinousse D., Sonet A., Tremisi P., Dumontet C., Moullet I., Eljaafaricorbin A., Neidhart-Berard E. M., Bouafia F., Coiffier B. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148–3155
- Kishita M., Motojima H., Oh-Eda M., Kojima T., Kamachi S., Fukushima M., Ono M. Stability of granulocyte colony-stimulating factor (G-CSF) in serum. The Clinical Report 1992; 26: 21
- Nissen C., Dalle V. Carbonare, Moser Y. In vitro comparison of the biological potency of glycosylated versus non glycosylated rG-CSF. Drug Investigation 1994; 7: 346–352
- De Arriba F., Lozano M. L., Ortuno F., Heras I., Moraleda J. M., Vicente V. Prospective randomized study comparing the efficacy of bioequivalent doses of glycosylated and non-glycosylated G-CSF for mobilizing blood progenitor cells. British Journal of Haematology 1997; 96: 418–420
- Höglund M., Smedmyr B., Bengtsson M., Tötterman T. H., Cour-Chabernaud V., Yver A., Simonsson B. Mobilization of CD34+ cells by glycosylated and non-glycosylated G-CSF in healthy volunteers — a comparative study. European Journal of Haematology 1997; 59: 177–183
- Watts M. J., Addison I., Long S. G., Hartley S., Warrington S., Boyce M., Linch D. C. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. British Journal of Haematology 1997; 97: 474–479
- Linch D. Activity in clinical settings: comparaison of PBSC mobilisation with different rG-CSFs in patients with lymphoma. International Journal of Hematology 1996; 64(Suppl. 2)S29
- Bensinger W., Appelbaum F., Rowley S., Storb R., Sanders J., Lilleby K., Gooley T., Demirer T., Schiffman K., Weaver C., Gift R., Chauncey T., Klarnet J., Montgomery P., Petersdorf S., Weiden P., Witherspoon R., Buckner C. D. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. Journal of Clinical Oncology 1995; 13: 2547–2555
- Haas R., Möhle R., Frühauf S., Goldschmidt H., Witt B., Flentje M., Waninenmacher M., Hunstein W. Patients characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–3794
- Siena S., Bregni M., Brando M., Ravagnani F., Bonadonna G., Gianni A. M. Circulation of CD34+ haematopoietic stem cells in the peripheral blood of high-dose of cyclophosphamide treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony stimulating factor. Blood 1989; 74: 1905–1914